French drugmaker Valneva said on Wednesday it will conduct a trial about the use of its COVID-19 vaccine candidate VLA2001 as a booster jab following a mRNA vaccination or natural infection.

Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront ...

French biotech firm Valneva said on Thursday its COVID-19 vaccine candidate was efficient as a booster for people who had received the same shot as an initial vaccination.

Valneva’s chief medical officer Juan Carlos Jaramillo said: “We reiterate our support for the precautionary measures that have been taken as well as our commitment to continue monitoring all ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term outlook despite near-term challenges.

Summary. Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva’s main ...

Valneva’s VALN shares surged 24.3% on Nov 10, after the company announced that it has entered into an advance purchase agreement (APA) with the European Commission (EC) for the supply of its ...

Saint-Herblain (France), November 9, 2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of ...

Valneva SE fell as much as 15% after the European Union slashed its order of the French company’s Covid-19 vaccine.. European countries will now buy 1.25 million doses of Valneva’s vaccine ...

5 Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ® - Valneva 6 Vaccines on the table as chikungunya outbreak intensifies in India - BlueDot ...